Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Completed
80 enrolled
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Phase 2 Completed
673 enrolled 22 charts
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Phase 1 Completed
65 enrolled
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Phase 1 Completed
110 enrolled
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Phase 2 Completed
58 enrolled
A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer
Phase 3 Completed
69 enrolled 5 charts
Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults
Phase 1 Completed
70 enrolled
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Phase 1/2 Completed
84 enrolled
Brain Metastasis in Breast Cancer Patients
Completed
1 enrolled
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
Phase 1 Completed
17 enrolled 7 charts
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Phase 1 Completed
105 enrolled
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Phase 1/2 Completed
12 enrolled
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Phase 2 Completed
51 enrolled
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
Phase 2 Completed
50 enrolled